CB-03 is under clinical development by Shanghai Zhimeng Biopharma and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CB-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CB-03 overview
CB-03 is under development for the treatment of epilepsy, amyotrophic lateral sclerosis, neuropathic pain, cancer pain and depression. It acts by targeting potassium voltage gated channel subfamily KQT member 2 and 3 (KCNQ2 and KCNQ3). It is administered through oral route.
Shanghai Zhimeng Biopharma overview
Shanghai Zhimeng Biopharma, Inc., is a biotech company with focus on discovering and developing innovative therapies for treating chronic hepatitis B virus infection and neurological diseases. The company is headquartered in China.
For a complete picture of CB-03’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
